What development phase is CRYPTENAMINE ACETATES in?

CRYPTENAMINE ACETATES is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

CRYPTENAMINE ACETATES

FDA-approved approved Quality 2/100

CRYPTENAMINE ACETATES is a marketed drug with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but it holds a significant competitive advantage due to its patent protection until 2028. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic name	CRYPTENAMINE ACETATES
Phase	FDA-approved
First approval	1982

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CRYPTENAMINE ACETATES CI brief — competitive landscape report
CRYPTENAMINE ACETATES updates RSS · CI watch RSS